R&D Strategy and Pipeline - BeiGene's R&D strategy focuses on developing a deep and impactful portfolio, executing fast-to-PoC for value maximization, initiating combination therapies early, and advancing only transformative medicines to late-stage development[18] - BeiGene has an extensive investment in innovative platforms, supporting a robust preclinical pipeline of 69 programs, with 51% biologics and 43% small molecules[19, 20] - BeiGene is transforming its pipeline with a focus on heme leadership and solid tumor diversification, expecting POC data readouts for many NMEs in the next 1-2 years[21] Solid Tumor Programs - BGB-43395 (CDK4i) is undergoing dose escalation in monotherapy and in combination with endocrine therapy (ET) in breast cancer patients[34] - Preliminary data from the BGB-43395-101 study shows a manageable safety profile, with diarrhea and nausea being the most commonly reported AEs[28] - BGB-43395 exhibits rapid absorption with a median Tmax of approximately 2 hours, and exposures increased approximately dose proportionately[42] Hematology Programs - Brukinsa (Zanubrutinib) - Brukinsa has demonstrated sustained PFS superiority over Ibrutinib in the ALPINE H2H study with 42.5 months follow-up, with a HR of 0.68 (95% CI: 0.54, 0.84)[74] - In the ALPINE study, Zanubrutinib showed sustained superiority and risk reduction in the TP53/Del17p population, with a HR of 0.51 (95% CI: 0.33, 0.78)[78, 80] - In the SEQUOIA study, Zanubrutinib demonstrated a sustained PFS benefit in treatment-naive unfit CLL/SLL patients, with a 71% reduction in risk of progression or death[88, 96] Hematology Programs - Sonrotoclax - In a Phase 1/1b study, Sonrotoclax combined with Zanubrutinib as frontline treatment for CLL demonstrated high MRD clearance rates, with 90% achieving uMRD by week 48 in the 320mg cohort[68, 122] - The CELESTIAL-TNCLL trial is an ongoing Phase 3 study assessing Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab for treatment-naive CLL[68, 142] Hematology Programs - BTK CDAC (BGB-16673) - In a Phase 1 study, the BTK degrader BGB-16673 showed an ORR of 77.6% in heavily pre-treated R/R CLL/SLL patients, with an ORR of 93.8% at 200 mg[169, 181] - BGB-16673 demonstrated promising activity in patients with Richter Transformation, with an ORR of 58.3%[175, 180] - BGB-16673 also showed high overall response rates and VGPRs in R/R WM patients, with an ORR of 81.5%[190, 193]

Company Overview - Aura Biosciences is developing virus-like drug conjugates (VDCs) targeting multiple solid tumor indications, including ocular and bladder cancers[7] - The company highlights a multi-billion dollar addressable market opportunity in early-stage choroidal melanoma (CM) and other ocular tumors[7] - Aura Biosciences expects to fund operations into 2025[7, 95] Ocular Oncology Program - Approximately 80% of choroidal melanoma patients are diagnosed with early-stage disease[21, 32] - Interim Phase 2 data showed that with 3 cycle regimens, the tumor control rate was 88.9% (8/9 patients)[44] - In the Phase 2 trial, vision preservation rate was 90% across all dose cohorts (20 patients)[52] Non-Muscle Invasive Bladder Cancer (NMIBC) Program - The company is targeting Non-Muscle Invasive Bladder Cancer, which affects over 200,000 patients per year globally[78] - Approximately 40% of intermediate-risk NMIBC patients experience failure of BCG/Chemo treatment[80] - Preclinical data demonstrates durable complete responses (CRs) with a single administration of Bel-sar in a bladder cancer model[82] Upcoming Milestones - The company plans to dose the first patient in the Phase 3 trial for primary choroidal melanoma in the first half of 2023[8, 95] - Phase 2 data for suprachoroidal administration in primary choroidal melanoma is expected in the second half of 2023[8, 95] - The company plans to initiate a Phase 2 trial in choroidal metastasis in the second half of 2023[8, 95]

Company Strategy & Vision - Soluna aims to drive the convergence of renewable energy and advanced computing infrastructure, converting wasted energy into value [13] - The company's business model involves sourcing low-cost curtailed power from IPPs, building and operating modular data centers (MDCs), attracting hosting customers, growing AUM & EBITDA, and expanding the project pipeline [32] - Soluna's approach tackles wasted energy through digital infrastructure, optimizing the grid, serving customers, and fueling growth to make renewable energy a superpower [31] Operational Highlights & Projects - Soluna has a 26 GW pipeline of wasted renewable energy to power its data centers [27] - The company aims to double its assets under management to 150 MW by the end of fiscal year 2024, focusing on constructing and energizing 48 MW of Project Dorothy 2 and breaking ground on Project Kati [26] - Soluna has over 478 MW of data center capacity in operation, construction, or development [63] - Project Kati has signed a PPA for 167 MW [59] - Project Rosa has a signed term sheet for 187 MW [59] Financial Performance - Soluna's revenue increased by 30% to $75 million in Q3 2024 compared to $58 million in Q3 2023 [72] - Year-to-date revenue for 2024 reached $297 million, a 172% increase compared to $109 million in 2023 [73, 77] - Year-to-date adjusted EBITDA for 2024 is $35 million, compared to a loss of $45 million in 2023 [74, 79] - Unrestricted cash increased 38% from the end of 2023, reaching $88 million [75]

CX-2051 Clinical Trial Results - CX-2051 demonstrated a confirmed Overall Response Rate (ORR) of 28% in patients with metastatic Colorectal Cancer (mCRC) [15, 31] - A higher ORR of 43% was observed at the 10 mg/kg dose [31] - The Disease Control Rate (DCR) was 94% in patients treated with 7.2-10 mg/kg of CX-2051 [15, 33] - Preliminary median Progression-Free Survival (PFS) was 5.8 months [15, 36] Safety and Tolerability - The Phase 1 study included 25 safety-evaluable patients treated with doses ranging from 2.4 to 10 mg/kg [28, 30] - Most Treatment-Related Adverse Events (TRAEs) were manageable and reversible, with no Grade 4-5 TRAEs reported [45] - In patients treated with 7.2-10 mg/kg, the most frequent TRAEs included diarrhea (78.3%), nausea (47.8%), and vomiting (34.8%) [45] - Serious Adverse Events occurred in 21.7% of patients [45] Future Development - Phase 1 dose expansions are underway in late-line mCRC [54, 56] - The company plans to initiate a Phase 2 study in the first half of 2026 [54]

Financial Performance & Growth - Harmony Biosciences achieved Q1 2025 net product revenue of $184.7 million, a 20% increase compared to $154.6 million in Q1 2024[10, 59] - The company reiterates its full-year 2025 revenue guidance of $820-$860 million[12] - Harmony Biosciences has over $600 million in cash, cash equivalents, and investments[5, 58] - WAKIX net revenue grew from $160 million in 2020 to $715 million in 2024[7] Pipeline Development & Catalysts - The company anticipates multiple milestones in 2025, with 6 Phase 3 development programs expected by year-end[62] - Topline data from the Phase 3 RECONNECT study of ZYN002 in Fragile X Syndrome is expected in Q3 2025[20, 22] - Phase 3 registrational trials of Pitolisant HD in narcolepsy and idiopathic hypersomnia are scheduled to begin in Q4 2025[20, 22, 41] - Preclinical data for BP1.15205, a potential best-in-class orexin-2 agonist, will be presented at SLEEP 2025 in June[20, 22, 24] Strategic Positioning & Market Opportunity - WAKIX is considered a potential $1B+ opportunity in narcolepsy alone[8, 12, 47] - The company is pursuing utility patents for pitolisant GR and pitolisant HD, potentially extending patent protection until 2044[20] - The company aims to establish a leadership position in CNS with a potential $3B+ opportunity[64]

Financials & Organization - The company had approximately $101 million in cash balance as of year-end 2024, which is expected to fund operations into Q2 2026, excluding potential milestones or new business development[6] - The company's organization consists of approximately 70 employees with integrated R&D capabilities[6] Clinical Pipeline (CX-2051) - CX-2051 (EpCAM PROBODY® Topo-1 ADC) is being developed for advanced CRC, with initial Phase 1 data expected in the first half of 2025 and determination of Phase 1b doses[7, 8] - Over 90% of CRC cases are estimated to have high EpCAM expression, making it a relevant target for CX-2051[32, 33] - In preclinical models, CX-2051 demonstrated >100x masking efficiency by ELISA and equivalent preclinical activity to deruxtecan (DXd) in irinotecan-resistant CRC models[22, 25] Clinical Pipeline (CX-801) - CX-801 (PROBODY® IFN-α2b) is being developed for advanced melanoma, with initial Phase 1 translational & biomarker data expected in the second half of 2025, and initiation of Keytruda® combination[7, 8] - Preclinical data suggests CX-801 has synergistic activity with PD-1 inhibitors and enhanced safety compared to unmasked IFNα2b[55] - CX-801 demonstrated 1000X masking efficiency based on preclinical models[54] Strategic Focus - The company is focused on addressing major unmet needs in oncology with its PROBODY® pipeline[4, 71] - The company plans to determine Phase 1b doses for potential CRC expansions and evaluate strategies for CRC combinations and additional tumor types for CX-2051[47, 72]

Mirum Pharmaceuticals: Transforming Lives in Rare Disease M a y 2 0 2 4 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our business strategy, objectives and opportunities, including the future opportunities ...

Amezalpat (TPST-1120) in HCC - Amezalpat randomized Phase 2 data in first-line HCC showed superiority to the Standard of Care (SoC) arm[6] - Overall Survival (OS) data revealed a six-month improvement with a stable hazard ratio of 0.65 compared to the control arm[6, 32, 35, 58] - Confirmed Objective Response Rate (ORR) in the ITT population was 30% in the Amezalpat + atezolizumab + bevacizumab arm compared to 13.3% in the atezolizumab + bevacizumab arm[32] - In PD-L1 negative patients, the confirmed ORR was 27% in the Amezalpat arm versus 7% in the SoC arm[32] - In patients with β-catenin mutations, the confirmed ORR in the Amezalpat arm was 43% with 100% Disease Control Rate (DCR)[32] Clinical Development and Regulatory - The FDA and EMA have agreed on a Phase 3 plan for Amezalpat[4, 48] - A pivotal Phase 3 study is designed with over 700 subjects and a 1:1 randomization[49] - The Phase 3 study has a critical hazard ratio of <0.805 for primary efficacy and <0.729 for early efficacy[49] - FDA granted Orphan Drug Designation in December 2024 and Fast Track Designation in January 2025[52] Market Opportunity - First-Line HCC is a large market, with 234,785 treated cases across the US, EU5, and China[54]

NTLA-2002 (Hereditary Angioedema - HAE) - NTLA-2002 aims to be the first to offer lifelong freedom from attacks and prophylaxis after a single dose for HAE, with a BLA submission planned in 2026[8] - Phase 2 study results showed 73% of patients were attack-free and off chronic prophylaxis after a single dose of NTLA-2002 at 16 weeks[37, 41] - The global market for HAE is projected to reach approximately $5 billion by 2028[8, 44] Nex-z (Transthyretin Amyloidosis - ATTR) - Nex-z aims to be the first to stabilize or reverse disease progression with a single dose for ATTR, with a BLA submission planned in 2028 for polyneuropathy[8] - Phase 1 data showed deep, rapid, and durable reductions in serum TTR, with an 89% reduction in ATTR-CM and a 90% reduction in ATTRv-PN at day 28[63] - The global market for ATTR is projected to reach approximately $12 billion by 2028[8, 86] Clinical Development and Milestones - Intellia expects three commercial launches starting in 2027[8] - The company plans to complete enrollment in the Phase 3 HAELO trial for NTLA-2002 in the second half of 2025 and the MAGNITUDE-2 trial for ATTRv-PN in 2026[2] - Intellia plans to enroll at least 550 patients in the Phase 3 MAGNITUDE trial for ATTR-CM in 2025 and complete enrollment in early 2027[2]

Portfolio & Performance - RLJ's urban-centric portfolio is expected to outperform the industry, with urban markets representing over two-thirds of the portfolio[3, 91] - In Q4, RLJ achieved 2.2% RevPAR growth, placing it in the top quartile of its peers[5] - Urban hotels, comprising two-thirds of the portfolio, experienced 3.7% RevPAR growth[8] - January 2025 RevPAR increased 3.2%, and February RevPAR increased 3.9%, primarily driven by ADR growth[11] Growth Initiatives - Phase I and II initiatives are projected to generate $14 million to $18 million of incremental EBITDA[3, 91] - RLJ acquired Hotel Teatro in Denver for $35.5 million in June 2024, with stabilized margins of approximately 32%[3, 38, 41] - Phase 2 conversions are expected to generate +$5 million-$6 million in incremental EBITDA[55] Capital Allocation & Balance Sheet - RLJ has approximately $0.9 billion of liquidity, providing optionality for growth[3, 90, 91] - The company repurchased $12.0 million of shares YTD through February 2025 and increased the dividend by 50% in 2024[3, 8, 90, 91] - RLJ recycled $22 million of non-core disposition proceeds into share repurchases in 2024[90] ESG & Sustainability - RLJ is active in social contribution with over $4 million in donations[105] - 76% of RLJ's properties utilize an environmental management system[101] - 56% of trustees are ethnically diverse, with 33% female[105]